Mimedx (MDXG) Liabilities and Shareholders Equity (2010 - 2026)

Mimedx has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $308.7 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $308.7 million, up 14.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 25.09% YoY), and the FY2025 annual result was $342.7 million, up 29.83% from the prior year.
• Liabilities and Shareholders Equity came in at $308.7 million for Q1 2026 at Mimedx, down from $342.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $342.7 million in Q4 2025 to a low of $168.2 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $230.2 million (2024), against an average of $232.4 million.
• Across the five-year window, Liabilities and Shareholders Equity slipped 9.87% in 2022 and jumped 39.44% in 2023, its largest moves.
• Mimedx's Liabilities and Shareholders Equity stood at $171.4 million in 2022, then jumped by 39.44% to $239.0 million in 2023, then gained by 10.4% to $263.9 million in 2024, then grew by 29.83% to $342.7 million in 2025, then declined by 9.92% to $308.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $308.7 million (Q1 2026), $342.7 million (Q4 2025), and $319.0 million (Q3 2025), per Business Quant data.